![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d3/Bremelanotide_structure.svg/640px-Bremelanotide_structure.svg.png&w=640&q=50)
Bremelanotide
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Bremelanotide?
Summarize this article for a 10 year old
Bremelanotide, sold under the brand name Vyleesi, is a medication used to treat low sexual desire in women.[2] Specifically it is used for low sexual desire which occurs before menopause and is not due to medical problems, psychiatric problems, or problems within the relationship.[3][4][2] It is given by an injection just under the skin of the thigh or abdomen.[2][4]
![]() | |
Clinical data | |
---|---|
Pronunciation | /ˌbrɛmɪˈlænətaɪd/ ⓘ |
Trade names | Vyleesi |
Other names | PT-141; Rekynda, bremelanotide acetate (USAN US) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619054 |
License data | |
Routes of administration | Subcutaneous[1] |
Drug class | Central nervous system agent |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | SCTooltip Subcutaneous injection: ~100%[1] |
Protein binding | 21%[1] |
Metabolism | Hydrolysis of peptide bonds[1] |
Elimination half-life | 2.7 hours[1] |
Excretion | Urine: 64.8% Feces: 22.8% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C50H68N14O10 |
Molar mass | 1025.182 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Common side effects include nausea, pain at the site of injection, and headache.[2] It may also cause a temporary increase in blood pressure and decrease in heart rate after each dose, and darkening of the gums, face, and breasts.[4] The medication is a peptide and acts by activating the melanocortin receptors.[1][5]
Bremelanotide was approved for medical use in the United States in 2019.[2][6] It was developed by Palatin Technologies.[7] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[8]